Vindico NanoBioTechnology Inc. (Vindico) is dedicated to the discovery, development and commercialization of highly innovative diagnostic and therapeutic applications based on its proprietary polymersome technology with a focus on the transfusion medicine market. Vindico is developing a revolutionary new class of nanoscale blood typing reagents for rapid, high throughput automated pre-transfusion testing. These Nanoscale Emissive Antibody-complexes for Typing (NEAT) reagents should represent the most significant advance in the field of blood typing since the introduction of agglutination reactions a century ago. Similarly, Vindico is developing worldâs first cellular hemoglobin-based oxygen therapeutic, NanoHeme, suitable as a clinical human blood substitut
